Close Menu
Home » Foundation Medicine Inks Cancer Biomarker Deal with J&J

Foundation Medicine Inks Cancer Biomarker Deal with J&J

Oct 26, 2011
Premium

Foundation Medicine has struck a deal with Johnson & Johnson Pharmaceutical Research and Development to use Foundation's targeted sequencing cancer test to identify potential biomarkers that could be of interest for the pharmaceutical company's clinical oncology programs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

GEDmatch Under New Owners

Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.

Generations of Bunnies

Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.

To Inform the Discussion

Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.

PNAS Studies on ER+ Breast Cancer Target, Skin Condition Gene Repair, Uveoretinitis

In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.

Dec
17
Featured Webinar

Non-Invasive Characterization of Solid Tumors via NGS Liquid Biopsy Testing

Sponsored by
Thermo Fisher Scientific

This webinar will review how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization.

What's Popular?

In Clinical Sequencing

  1. Adaptive Biotechnologies, AbbVie Partner on MRD Testing in Multiple Myeloma Drug Trials

  2. ASH Study: Germline Testing Identifies Cancer Risk Mutations, VUS in Older AML Patients

  3. Gene Panel Finds Pathogenic Variants Missed by Standard Tests in 5 Percent of Familial Cancer Cases

  4. Childhood Kidney Cancer Arises From Altered Normal Tissue, Sequencing Study Finds

  5. Enpicom, Cytura Therapeutics to Develop Cancer Diagnostic

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.